Abbvie poised to buy Apogee Therapeutics for $11 billion, reveals the Financial Times
Just when it had gone a tad quiet in the world of biotechnology dealmaking Oliver "an Englishman in New York" Barnes of the venerable Financial Times pops up with another corking scoop.
You need to register and sign in to read this content.
